Takemichi Fukasawa

List of Publications by Year in descending order

38 papers	593 citations	687363 13 h-index	677142 22 g-index
39 all docs	39 docs citations	39 times ranked	555 citing authors

#	Article	IF	Citations
1	Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatology, The, 2021, 3, e489-e497.	3.9	105
2	Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 1879-1890.	5.6	47
3	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with antiâ€topoisomerase Iâ€positive systemic sclerosisâ€associated interstitial lung disease. Journal of Dermatology, 2019, 46, 1006-1013.	1.2	47
4	Cytokine analysis on a countable number of molecules from living single cells on nanofluidic devices. Analyst, The, 2019, 144, 7200-7208.	3.5	39
5	Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nature Communications, 2021, 12, 5947.	12.8	38
6	Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model. ELife, 2021, 10, .	6.0	32
7	Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. Arthritis Research and Therapy, 2019, 21, 129.	3.5	29
8	The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. European Journal of Cancer, 2013, 49, 3547-3558.	2.8	24
9	Serineâ€“Threonine Kinase 38 regulates CDC25A stability and the DNA damage-induced G2/M checkpoint. Cellular Signalling, 2015, 27, 1569-1575.	3.6	22
10	Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in antiâ€melanoma differentiationâ€associated gene 5 antibodyâ€positive dermatomyositis. Journal of Dermatology, 2020, 47, 483-489.	1.2	22
11	Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatology, The, 2022, 4, e546-e555.	3.9	21
12	Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReSâ€,trial. Rheumatology, 2022, 61, 4364-4373.	1.9	18
13	B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. Arthritis and Rheumatology, 2021, 73, 2086-2095.	5.6	17
14	Serum interleukinâ€34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease. Journal of Dermatology, 2018, 45, 1216-1220.	1.2	16
15	Critical contribution of the interleukinâ€6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis. Journal of Dermatology, 2017, 44, 967-971.	1.2	14
16	Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. Annals of the Rheumatic Diseases, 2016, 75, 1858-1865.	0.9	12
17	Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. Scandinavian Journal of Rheumatology, 2017, 46, 247-252.	1.1	9
18	Interleukin (IL)â€17F and ILâ€17E are related to fibrosis and vasculopathy in systemic sclerosis. Journal of Dermatology, 2020, 47, 1287-1292.	1.2	9

#	Article	IF	Citations
19	Rapid alteration of serum interleukinâ€6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosisâ€associated interstitial lung disease. Journal of Dermatology, 2018, 45, 1221-1224.	1.2	8
20	Prevention of calpain-dependent degradation of STK38 by MEKK2-mediated phosphorylation. Scientific Reports, 2019, 9, 16010.	3.3	7
21	Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia. International Journal of Hyperthermia, 2022, 39, 200-208.	2.5	7
22	Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. Frontiers in Immunology, 2022, 13, .	4.8	7
23	Pharmacotherapy of Itchâ€”Antihistamines and Histamine Receptors as G Protein-Coupled Receptors. International Journal of Molecular Sciences, 2022, 23, 6579.	4.1	7
24	Percentage of residual B cells after 2Âweeks of rituximab treatment predicts the improvement of systemic sclerosisâ€associated interstitial lung disease. Journal of Dermatology, 2022, 49, 179-183.	1.2	6
25	Assessment of endothelial function during the loading phase of infliximab in psoriasis: a potential predictor of its drug survival. International Journal of Dermatology, 2019, 58, 54-59.	1.0	5
26	Expert-Level Distinction of Systemic Sclerosis from Hand Photographs Using Deep Convolutional Neural Networks. Journal of Investigative Dermatology, 2021, 141, 2536-2539.	0.7	5
27	Rapid decrease of serum surfactant proteinâ€D levels predicts the reactivity of rituximab therapy in systemic sclerosisâ€associated interstitial lung disease. Journal of Dermatology, 2020, 47, 796-800.	1.2	4
28	Successful treatment with rituximab in a Japanese patient with systemic sclerosisâ€associated interstitial lung disease resistant to oral steroid and cyclophosphamide. Journal of Dermatology, 2018, 45, e140-e141.	1.2	3
29	Development of a prediction model of treatment response in patients with cutaneous arteritis: Insights from a cohort of 33 patients. Journal of Dermatology, 2021, 48, 1021-1026.	1.2	3
30	Serum levels of human Î²â€defensin 2: possible association with fibrosis and vasculopathy in patients with systemic sclerosis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e272-e274.	2.4	2
31	Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association with Interstitial Lung Disease. Journal of Clinical Medicine, 2021, 10, 660.	2.4	2
32	Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. Diagnostics, 2021, 11, 2274.	2.6	2
33	Single B cell analysis can reveal distinct cytokine profile of autoreactive B cells in systemic sclerosis. Journal of Dermatological Science, 2017, 86, e7-e8.	1.9	1
34	Exacerbated Immune Complex-Mediated Vascular Injury in Mice with Heterozygous Deficiency of Aryl Hydrocarbon Receptor through Upregulation of FcÎ³ Receptor III Expression on Macrophages. Journal of Investigative Dermatology, 2018, 138, 2195-2204.	0.7	1
35	Serum Calponin 3 Levels in Patients with Systemic Sclerosis: Possible Association with Skin Sclerosis and Arthralgia. Journal of Clinical Medicine, 2021, 10, 280.	2.4	1
36	Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration. Life, 2022, 12, 646.	2.4	1

#	Article	IF	Citations
37	060 The cytokine production of autoantigen-reactive B cells associates with pathogenesis in systemic sclerosis. Journal of Investigative Dermatology, 2018, 138, S10.	0.7	0
38	COVID-19 pandemic highlighted the importance of telemedicine in the collagen disease of systemic sclerosis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 160.	0.8	0